Related Experiment Video

Updated: Aug 14, 2026

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

Paclitaxel resistance in cells with reduced beta-tubulin

Yaqing Wang1, Fernando Cabral

  • 1Department of Integrative Biology and Pharmacology, University of Texas Medical School, Houston, 77030, USA.

Biochimica Et Biophysica Acta
|June 14, 2005
PubMed

Insights

Revertant cells with less tubulin showed reduced colcemid resistance but increased paclitaxel resistance. This suggests that lower tubulin levels may be a novel mechanism for paclitaxel resistance in cancer cells.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Genetics

Background:

  • Chinese hamster ovary (CHO) cell lines with alpha- and beta-tubulin mutations were previously developed for colcemid resistance, exhibiting increased microtubule assembly and stability.
  • Colcemid resistance in these cell lines is linked to specific tubulin mutations affecting microtubule dynamics.

Purpose of the Study:

  • To investigate the reversion mechanisms from colcemid resistance in beta-tubulin mutant CHO cells.
  • To determine the relationship between tubulin levels, colcemid sensitivity, and paclitaxel resistance.

Main Methods:

  • Analysis of colcemid-sensitive revertants derived from beta-tubulin mutant CHO cells.
  • Quantification of tubulin levels and assessment of tubulin polymerization.
  • Evaluation of paclitaxel resistance in revertant cells and wild-type cells.
  • Functional complementation studies using beta-tubulin cDNA transfection.

Main Results:

  • Loss or inactivation of the mutant beta-tubulin allele was the predominant reversion mechanism.
  • Revertant cells displayed a 35% reduction in steady-state tubulin levels and normal tubulin polymerization.
  • Revertant cells showed increased resistance to paclitaxel compared to wild-type cells.
  • Transfection with wild-type beta-tubulin cDNA suppressed paclitaxel resistance, confirming its link to reduced tubulin.

Conclusions:

  • The most common mechanism for reversion of colcemid resistance in these cells is the loss or inactivation of the mutant beta-tubulin allele.
  • Reduced cellular tubulin levels, resulting from the loss of the mutant allele, confer increased resistance to paclitaxel.
  • Lowering tubulin levels represents a potential novel mechanism of paclitaxel resistance, offering new insights into cancer therapy resistance.

More Related Videos

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel08:29

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Published on: May 14, 2018

Related Concept Videos

Destabilization of Microtubules01:45

Destabilization of Microtubules

The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...